Business & Profession

Can Hoya IOLs regain market position after being withdrawn for the best part of a year?

What is SCHWIND eye-tech-solutions known for? We develop, produce and market a comprehensive product portfolio for the treatment of ametropia and corneal diseases. This includes diagnostic systems, software modules for individual treatment planning, and nanosecond and excimer laser systems.

How do you translate a good idea into a physical, purchasable product? Technical, medical, regulatory and business skills are a must, as is an immense ability to resist pressure – especially when your device measures it.

With an ever-growing market and new treatment options on hand, presbyopia offers an attractive business proposition. Understanding the patient and building your practice around her/him is key to success. Here’s how we have done it.

Well over 1,000 different proteins have been cataloged in the vitreous humor. Here’s how they break down.

Retinal implants offer hope for the treatment of inherited blindness. Clinical trials of battery-powered subretinal and epiretinal devices have demonstrated that patients with retinitis pigmentosa, blind for many years, can once again recognize objects.

In the event of an oculolinctus craze, we are ready (thanks to The Daily Mail and others). This summer, Western media leapt upon a post on Japanese curation site Naver Matome which detailed a sudden increase in the practice of oculolinctus.

A stark picture of an overstretched, fragile service, often at odds with hospital management, is painted in a recent RCO report. What can be done?

Free glaucoma simulation app reinforces the importance of taking medication. A recently-launched free app for iPhones and iPads will help newly diagnosed glaucoma patients better understand how the condition will affect their vision as it worsens, reinforcing the importance of taking prescribed eye drops and attending eye clinic.

Why the pharmaceutical industry is making acquisitions in ophthalmology – and why it won’t stop. The world’s pharmaceutical companies have fallen heavily for the charms of ophthalmology in recent times, with a string of acquisitions and product launches, including: